Research

Energy balance

The evidence supporting GLP-1RAs for treating PsO and PsA remains limited.

Further clinical research is needed to establish the efficacy and safety of GLP-1RAs for PsO and PsA.

StrongQualifiesmedium confidence
Although promising, the evidence supporting GLP-1RAs for treating PsO and PsA remains limited.
Dimitri Luz Felipe da Silva et al. · The Journal of Rheumatology · 2025

Why this rating

The claim is based on the authors' assessment of the current research landscape.

Source

What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists

Dimitri Luz Felipe da Silva et al. · The Journal of Rheumatology · 2025

DOI 10.3899/jrheum.2025-0531

reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →